Ramipril pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "ramipril pharmacology"
Ramipril Pharmacology: Mechanism of Action and Drug Class
Ramipril is a long-acting angiotensin-converting enzyme (ACE) inhibitor, similar in its pharmacodynamic properties to other ACE inhibitors like captopril and enalapril. It is a prodrug, meaning it is converted in the body to its active form, ramiprilat, after absorption. This conversion allows for a long elimination half-life, making once-daily dosing effective for most patients .
Pharmacokinetics: Absorption, Metabolism, and Elimination
After oral administration, ramipril is hydrolyzed in the liver to ramiprilat, the active metabolite responsible for its therapeutic effects. The absolute oral bioavailability of ramipril is about 15% in its unchanged form and 44% as ramiprilat in plasma. Ramiprilat’s long half-life supports sustained blood pressure control with once-daily dosing 15.
Pharmacokinetic studies show that body composition, especially fat-free mass, influences ramipril and ramiprilat levels in the body. Ramipril clearance is affected by patient age and daily dose, while ramiprilat clearance is influenced by kidney function (glomerular filtration rate) and daily dose. However, the pharmacokinetics of ramipril remain relatively stable over time, supporting regular outpatient monitoring every six months for patients on long-term therapy .
Pharmacogenetics: Genetic Variability in Ramipril Response
Genetic differences can significantly impact how individuals process ramipril. Variations in the SLCO1B1 and ABCG2 genes, which code for important drug transporters, have been shown to strongly affect ramipril exposure in the body. Individuals with decreased function in these genes may have higher levels of ramipril, which could influence both efficacy and risk of side effects. Further research is needed to clarify the clinical significance of these findings .
Therapeutic Uses: Hypertension, Heart Failure, and Proteinuria
Ramipril is widely used to treat high blood pressure (hypertension) and congestive heart failure. Doses ranging from 2.5 to 20 mg daily are effective for blood pressure control, and ramipril is comparable in efficacy to other common antihypertensive agents like captopril, enalapril, and atenolol. For patients who do not respond to ramipril alone, adding a diuretic can improve outcomes .
In patients with chronic heart failure, ramipril helps reduce the risk of worsening heart failure, hospitalizations, and death. Its stable pharmacokinetics make it suitable for long-term management in these patients .
Ramipril also has a significant effect in reducing proteinuria (protein in the urine), which is important for protecting kidney function. Higher and divided doses of ramipril maximize this antiproteinuric effect, especially during the night, likely due to better pharmacological coverage .
Alternative Formulations and Administration Routes
Research into alternative delivery methods, such as transdermal films, has shown that ramipril can achieve sustained release and increased bioactivity compared to conventional oral or intravenous administration. Transdermal application in animal models resulted in prolonged drug action and greater reduction in intraocular pressure, suggesting potential for improved therapeutic outcomes in specific settings .
Additional Effects: Anti-Inflammatory and Immunomodulatory Properties
Beyond its cardiovascular benefits, ramipril has demonstrated anti-inflammatory and immunomodulatory effects in animal models of arthritis. It reduced inflammation, improved biochemical and hematological parameters, and preserved joint structure, indicating potential benefits in inflammatory conditions. However, more research is needed to fully understand these effects in humans .
Comparative Efficacy and Safety
Ramipril is as effective as other antihypertensive agents, such as moxonidine, in lowering blood pressure in patients with hypertension and metabolic disorders like diabetes. Both drugs are well tolerated and have minimal impact on metabolic parameters, making ramipril a suitable choice for patients with comorbid conditions .
Conclusion
Ramipril is a well-established ACE inhibitor with proven efficacy in treating hypertension, heart failure, and proteinuria. Its pharmacokinetics are influenced by genetic and physiological factors, but remain stable over time, supporting its use in long-term therapy. Alternative formulations and additional anti-inflammatory effects are areas of ongoing research, further expanding the potential applications of ramipril in clinical practice 1234+3 MORE.
Sources and full results
Most relevant research papers on this topic
Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.
Ramipril is a useful alternative ACE inhibitor for treating hypertension and congestive heart failure, with comparable efficacy to captopril, enalapril, and atenolol.
SLCO1B1 and ABCG2 genotype‐informed phenotypes are related to variation in ramipril exposure
SLCO1B1 and ABCG2 genetic variations significantly alter ramipril exposure, with decreased function phenotypes indicating higher exposure and increased risk of adverse drug reactions.
How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT—a prospective cohort study
Ramipril effectively reduces proteinuria at all tested doses, with high and divided doses maximizing the antiproteinuric effect, possibly due to better pharmacological coverage of the nocturnal period.
Formulation and administration of ramipril prodrug for improving bioactivity significantly: In vitro and in vivo correlation
Transdermal administration of ramipril significantly improves bioactivity and prolongs ocular hypotensive action compared to conventional oral and intravenous administration.
Фармакоэкономические аспекты эффективности ингибиторов ангиотензин-превращающего фермента при артериальной гипертонии у пациентов с высоким сердечно-сосудистым риском
The original ramipril (Trirace) is the safest and most expensive drug for treating hypertension in patients with high cardio-vascular risk, while generics of ramipril (Fosicard) have better safety profiles.
Modification of Radiation Injury by Ramipril, Inhibitor of Angiotensin-Converting Enzyme, on Optic Neuropathy in the Rat
Ramipril significantly reduces radiation-induced optic neuropathy in rats, providing a potential pharmacological strategy to reduce radiation-induced normal tissue damage.
DOI